Search research articles
Contact Us
Filters
Showing results (41-50 of 60) with videos related to
Page
of 6
Sort By:
The New England Journal of Medicine
|
December 14, 2016
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, et al.
The Lancet. Oncology
|
October 19, 2016
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss, Chun-Ming Tsai, Frances A Shepherd, et al.
Radiology
|
August 15, 2012
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity
Christina Messiou, Matthew Orton, Joo Ern Ang, et al.
Clinical Lung Cancer
|
August 31, 2025
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study
Niels Reinmuth, Jonathan W Goldman, Yuanbin Chen, et al.
British Journal of Cancer
|
October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 22, 2023
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2022
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Gilberto de Castro, Naiyer A Rizvi, Peter Schmid, et al.
Clinical Lung Cancer
|
April 7, 2024
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study
Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2026
Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564]
Silvia Novello, David R Spigel, Jian Fang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 1, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial
Silvia Novello, Ying Cheng, David Spigel, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 60) with videos related to
Sort By:
Page
of 6
The New England Journal of Medicine
|
December 14, 2016
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, et al.
The Lancet. Oncology
|
October 19, 2016
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss, Chun-Ming Tsai, Frances A Shepherd, et al.
Radiology
|
August 15, 2012
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity
Christina Messiou, Matthew Orton, Joo Ern Ang, et al.
Clinical Lung Cancer
|
August 31, 2025
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study
Niels Reinmuth, Jonathan W Goldman, Yuanbin Chen, et al.
British Journal of Cancer
|
October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 22, 2023
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2022
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Gilberto de Castro, Naiyer A Rizvi, Peter Schmid, et al.
Clinical Lung Cancer
|
April 7, 2024
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study
Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2026
Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564]
Silvia Novello, David R Spigel, Jian Fang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 1, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial
Silvia Novello, Ying Cheng, David Spigel, et al.
Page
of 6